Top

Published in:

Open Access 01-12-2018 | Correction

Correction to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway

Authors: Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu, Xiao-Rong Dong

Published in: Journal of Hematology & Oncology | Issue 1/2018

Excerpt

The original article [1] contained incorrect affiliations for the authors. …

Wei C-H, et al. MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway. J Hematol Oncol. 2017;10:125.CrossRefPubMedPubMedCentral

Title: Correction to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway
Authors: Chun-Hua Wei
Gang Wu
Qian Cai
Xi-Can Gao
Fan Tong
Rui Zhou
Rui-Guang Zhang
Ji-Hua Dong
Yu Hu
Xiao-Rong Dong
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2018
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-017-0546-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy

Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide

Keynote webinar | Spotlight on antibody–drug conjugates in cancer